How Drug Pricing Reflects National Values Comparing the U.S. and Europe
- 2 May 2026
- book chapter
- Published by IGI Global Scientific Publishing
- p. 25-54
Abstract
This article analyzes how national values shape pharmaceutical pricing, comparing the United States and Europe as distinct political economies of health. Drug prices reflect not only market forces but the moral and institutional choices by which societies balance innovation, equity, and fiscal legitimacy. The U.S. model, delegated capitalism, links public research to private profit, generating rapid innovation but deep inequality. The European model, embedded corporatism, ties reimbursement to therapeutic value, achieving solidarity yet slower adoption. Tracing postwar development through the 2008 financial crisis and COVID-19, the study shows how both systems adapt under stress and how transatlantic interaction now defines global norms of affordability, state authority, and technological sovereignty.Keywords
This publication has 18 references indexed in Scilit:
- New Reforms to Prescription Drug Pricing in the USJAMA, 2022
- Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysisThe Lancet Oncology, 2020
- Proposals to Redesign Medicare Part D — Easing the Burden of Rising Drug PricesNew England Journal of Medicine, 2019
- Patient Advocacy Organizations, Industry Funding, and Conflicts of InterestJAMA Internal Medicine, 2017
- How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European CountriesApplied Health Economics and Health Policy, 2017
- The Palgrave International Handbook of Healthcare Policy and Governance2015
- Trojan Multilateralism: Global Cooperation in HealthGlobal Policy, 2013
- The New Political Economy of Pharmaceuticals2013
- Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysisHealth Policy, 2007
- Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence comparedHealth Policy, 2006